HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$30.23
Day range
$29.19 - $30.56
Year range
$27.69 - $76.98
Market cap
1.52B USD
Avg Volume
301.05K
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 80.25M | 23.74% |
Operating expense | 37.35M | 0.44% |
Net income | 8.74M | 864.24% |
Net profit margin | 10.89 | 677.86% |
Earnings per share | 0.13 | 226.75% |
EBITDA | -7.47M | 42.86% |
Effective tax rate | -43.38% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 901.28M | 102.93% |
Total assets | 1.08B | 91.51% |
Total liabilities | 706.81M | 235.62% |
Total equity | 377.83M | — |
Shares outstanding | 50.03M | — |
Price to book | 4.00 | — |
Return on assets | -2.02% | — |
Return on capital | -2.51% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 8.74M | 864.24% |
Cash from operations | 21.13M | 109.41% |
Cash from investing | -828.00K | -290.57% |
Cash from financing | 198.00K | -98.09% |
Net change in cash | 32.78M | 169.97% |
Free cash flow | 24.65M | 368.96% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
497
